MXCT · Maxcyte, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MXCT
this stock
Maxcyte, Inc.
|
$127.98M | -20.0% | -14.5% | — | 1.2% |
|
ABT
Abbott Laboratories
|
$192.64B | -13.1% | +5.7% | 31.0 | 1.2% |
|
SYK
Stryker Corp
|
$121.41B | -9.7% | +11.2% | 32.8 | 1.8% |
|
MDT
Medtronic plc
|
$117.82B | -4.2% | +8.4% | 24.7 | 1.1% |
|
BSX
Boston Scientific Corp
|
$70.00B | -49.6% | +12.5% | 19.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MXCT | -8.2% | +11.7% | +53.5% | -3.9% | -20.0% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -7.6% | +13.0% | +40.8% | -3.2% | -31.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.